Search clinical trials for: 8.0 mg PF-06649751

Total 724 results

Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Pfizer

Terminated

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease With Motor Fluctuations

United States
BioMarin Pharmaceutical

Terminated

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, Netherlands, France, United Kingdom, Italy
AO GENERIUM

Recruiting

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Completed

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

Healthy

United States
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

Parkinson's Disease

United States, Belgium
aTyr Pharma, Inc.
Foundation for Sarcoidosis Research

Completed

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

United States
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Cerevel Therapeutics, LLC

Completed

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

Parkinson Disease

United States
Cerevel Therapeutics, LLC

Enrolling by invitation

Open-label Trial in Parkinson's Disease (PD) (TEMPO-4)

Parkinson Disease

Poland, United States, Spain, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Serbia, Ukraine
Cerevel Therapeutics, LLC

Active, not recruiting

Fixed-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-1)

Parkinson Disease

Spain, United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Israel, Italy, Poland, Ukraine
Cerevel Therapeutics, LLC

Active, not recruiting

Flexible-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-2)

Parkinson Disease

Poland, Spain, United States, France, Germany, Hungary, Italy, Serbia, Ukraine, Australia, Korea, Republic of, Taiwan, Thailand
Regado Biosciences, Inc.

Completed

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD (SC101)

Healthy Volunteer

United States
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Parkinson Disease

United States, France, Israel, Germany
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Novo Nordisk A/S

Completed

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Obesity

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Apathy in Dementia

United States, Canada
Pfizer

Completed

Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Cerevel Therapeutics, LLC

Completed

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

Parkinson Disease

Germany, Spain, United States, Australia, Bulgaria, Czechia, France, Israel, Italy, Poland, Ukraine, Serbia
Bausch Health Americas, Inc.

Completed

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Ablynx

Completed

Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection (Respire)

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Belgium, Hungary, Israel, Spain, Estonia, Philippines, Thailand, Bulgaria, Poland, Germany, Chile, Colombia, Croatia, Czechia, Latvia, Malaysia, Slovakia
Cara Therapeutics, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Pruritus | Notalgia Paresthetica

United States, Poland, Spain, Canada, Germany
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Novo Nordisk A/S

Completed

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

Diabetes Mellitus, Type 2

Germany
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Bausch Health Americas, Inc.

Completed

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation (CIC)

Chronic Idiopathic Constipation

United States
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
ReveraGen BioPharma, Inc.
University of Pittsburgh; Cooperative International Neuromuscular Research...

Completed

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
Pfizer

Completed

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Diabetes Mellitus, Type 2

United States, Colombia, Spain, Germany, Sweden, Italy
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Pfizer

Completed

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

Healthy

United States
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Active, not recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
Pfizer

Completed

A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

Healthy

Netherlands
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Dry Eye Disease

United States
Pfizer

Completed

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Overweight and/or Obesity

Belgium

3

Subscribe